Anthony L Cunningham Selected Research

Herpes Zoster Vaccine

11/2022	Association Between Immunogenicity and Reactogenicity: A Post Hoc Analysis of 2 Phase 3 Studies With the Adjuvanted Recombinant Zoster Vaccine.
1/2022	The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70.
12/2021	Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares.
1/2021	The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials.
1/2021	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
12/2020	Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine.
11/2020	Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.
1/2019	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anthony L Cunningham Research Topics

Disease

33	Infections 01/2021 - 04/2002
20	Herpes Zoster 01/2022 - 09/2002
6	HIV Infections (HIV Infection) 01/2021 - 02/2004
6	Herpes Genitalis (Genital Herpes) 01/2020 - 09/2002
4	Human Influenza (Influenza) 12/2016 - 08/2009
3	COVID-19 01/2022 - 01/2021
3	Chickenpox 01/2020 - 09/2002
3	Herpes Simplex 01/2020 - 10/2002
3	Postherpetic Neuralgia 01/2018 - 09/2002
3	Acquired Immunodeficiency Syndrome (AIDS) 12/2007 - 07/2005
2	Pain (Aches) 11/2022 - 09/2002
2	Inflammation (Inflammations) 01/2022 - 09/2010
2	Exanthema (Rash) 01/2019 - 09/2010
2	Coinfection 05/2015 - 02/2004
2	Latent Infection 11/2009 - 04/2004
2	Tuberculosis (Tuberculoses) 08/2009 - 07/2009
1	Lymphocytosis 01/2022
1	Gout 12/2021
1	Pneumococcal Pneumonia 01/2021
1	Pneumococcal Infections 01/2021
1	Frailty 01/2021
1	Persistent Infection 10/2017
1	Tetanus 12/2016
1	Asymptomatic Infections 12/2007
1	Viremia 11/2007
1	Ulcer 03/2007
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 03/2007

Drug/Important Bio-Agent (IBA)

21	VaccinesIBA 01/2021 - 11/2002
8	Herpes Zoster VaccineIBA 11/2022 - 01/2019
8	Antiviral Agents (Antivirals)IBA 01/2021 - 09/2002
8	Subunit VaccinesIBA 01/2018 - 11/2002
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 04/2002
5	CytokinesIBA 01/2022 - 01/2003
5	Glycoproteins (Glycoprotein)IBA 01/2016 - 10/2002
4	ChemokinesIBA 01/2022 - 01/2003
4	InterferonsIBA 01/2021 - 09/2006
4	AntibodiesIBA 12/2016 - 09/2002
3	Viral ProteinsIBA 01/2020 - 02/2005
3	AntigensIBA 01/2020 - 09/2002
3	Biological ProductsIBA 05/2014 - 07/2005
3	Anti-Infective Agents (Microbicides)IBA 01/2013 - 02/2004
2	Peptides (Polypeptides)IBA 01/2021 - 08/2009
2	Acyclovir (Aciclovir)FDA LinkGeneric 01/2021 - 01/2004
2	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 01/2021 - 12/2016
2	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 09/2006
2	Polysaccharides (Glycans)IBA 01/2021 - 01/2016
2	varicella-zoster virus glycoprotein EIBA 01/2018 - 09/2016
2	AS01B adjuvantIBA 01/2018 - 09/2016
2	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2016 - 12/2016
2	C-Type Lectins (C-Type Lectin)IBA 01/2016 - 11/2003
2	DNA (Deoxyribonucleic Acid)IBA 05/2015 - 08/2011
2	Neuraminidase (Sialidase)IBA 08/2011 - 07/2010
2	Oseltamivir (Tamiflu)FDA Link 07/2010 - 12/2009
2	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 06/2007 - 12/2004
1	Biomarkers (Surrogate Marker)IBA 11/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	NectinsIBA 01/2021
1	Attenuated VaccinesIBA 12/2020
1	PlasticsIBA 01/2020
1	Formaldehyde (Formol)FDA Link 01/2019
1	ParaffinIBA 01/2019
1	HemocyaninsIBA 02/2016
1	LectinsIBA 01/2016
1	Viral HemagglutininsIBA 01/2016
1	ClathrinIBA 01/2016
1	Mannose (D-Mannose)IBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	N-Acetylneuraminic Acid (Sialic Acid)IBA 01/2016
1	CaveolinsIBA 01/2016
1	Dynamins (Dynamin)IBA 01/2016
1	Histocompatibility Antigens Class IIIBA 03/2014
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 10/2013
1	LipidsIBA 07/2012
1	OligonucleotidesIBA 08/2011
1	jasplakinolideIBA 09/2010
1	Viral AntigensIBA 09/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2010
1	Interleukin-10 (Interleukin 10)IBA 11/2009
1	Streptokinase FDA Link 08/2009
1	Tetanus Toxoid (Vaccine, Tetanus)FDA Link 08/2009
1	Tryptophan (L-Tryptophan)FDA Link 07/2009
1	Complementary DNA (cDNA)IBA 07/2009
1	Surface Antigens (Surface Antigen)IBA 11/2007
1	HIV Core Protein p24IBA 09/2007
1	AIDS VaccinesIBA 09/2007
1	HIV AntibodiesIBA 09/2007
1	Contraceptive Agents (Contraceptives)IBA 03/2007
1	ImmunosorbentsIBA 03/2007
1	Immunoglobulin G (IgG)IBA 03/2007
1	EnzymesIBA 03/2007
1	Local Anti-Infective Agents (Antiseptics)IBA 12/2006
1	TAK 779IBA 07/2005
1	Protein Isoforms (Isoforms)IBA 04/2005
1	Chemokine CXCL12IBA 04/2005
1	Dyneins (Dynein)IBA 07/2004

Therapy/Procedure

2	Therapeutics 01/2021 - 09/2002
1	Drug Therapy (Chemotherapy) 01/2022
1	Highly Active Antiretroviral Therapy (HAART) 11/2007
1	Condoms (Condom) 12/2006